ATE318143T1 - Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe - Google Patents
Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexeInfo
- Publication number
- ATE318143T1 ATE318143T1 AT97912811T AT97912811T ATE318143T1 AT E318143 T1 ATE318143 T1 AT E318143T1 AT 97912811 T AT97912811 T AT 97912811T AT 97912811 T AT97912811 T AT 97912811T AT E318143 T1 ATE318143 T1 AT E318143T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- acid ligand
- vegf
- growth factor
- cell growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/739,109 US5859228A (en) | 1995-05-04 | 1996-10-25 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US08/870,930 US6168778B1 (en) | 1990-06-11 | 1997-06-06 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US08/897,351 US6051698A (en) | 1997-06-06 | 1997-07-21 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE318143T1 true ATE318143T1 (de) | 2006-03-15 |
Family
ID=27419245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97912811T ATE318143T1 (de) | 1996-10-25 | 1997-10-17 | Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1685842A3 (de) |
JP (2) | JP3626503B2 (de) |
KR (1) | KR100514929B1 (de) |
AT (1) | ATE318143T1 (de) |
AU (1) | AU733674B2 (de) |
CA (1) | CA2269072C (de) |
DE (3) | DE69735292T2 (de) |
DK (1) | DK0957929T3 (de) |
ES (1) | ES2259188T3 (de) |
FR (1) | FR06C0021I2 (de) |
GE (1) | GEP20094799B (de) |
IL (2) | IL129497A0 (de) |
LU (1) | LU91252I2 (de) |
NL (1) | NL300234I2 (de) |
NZ (1) | NZ334859A (de) |
PT (1) | PT957929E (de) |
RU (1) | RU2177950C2 (de) |
WO (1) | WO1998018480A1 (de) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US6346611B1 (en) * | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
US6762290B1 (en) * | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
AU782620B2 (en) * | 1991-06-10 | 2005-08-11 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
CZ2002140A3 (cs) * | 1999-07-14 | 2002-05-15 | Alza Corporation | Neutrální lipopolymer a lipozomové kompozice, které jej obsahují |
EP2351855A1 (de) * | 2000-09-26 | 2011-08-03 | Duke University | RNA-Aptamere und Verfahren zu ihrer Identifizierung |
EP2431377B1 (de) * | 2001-10-26 | 2017-04-19 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
EP1441743A4 (de) * | 2001-11-09 | 2009-02-25 | Eyetech Pharmaceuticals | Verfahren zur behandlung von neovaskulären augenerkrankungen |
US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
CA2492463A1 (en) | 2002-07-25 | 2004-02-05 | Archemix Corporation | Regulated aptamer therapeutics |
US9303262B2 (en) | 2002-09-17 | 2016-04-05 | Archemix Llc | Methods for identifying aptamer regulators |
US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
EP1570085A4 (de) * | 2002-12-03 | 2007-07-25 | Archemix Corp | Verfahren zur in-vitro-selektion 2'-substituierter nukleinsäuren |
FR2852606A1 (fr) * | 2003-03-18 | 2004-09-24 | Inst Nat Sante Rech Med | Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie |
CA2523260A1 (en) | 2003-04-21 | 2004-11-04 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
CL2004001996A1 (es) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion. |
EP3385384B1 (de) | 2004-02-12 | 2020-04-08 | Archemix LLC | Aptamer-therapeutika zur behandlung von mit dem komplementsystem in verbindung stehenden erkrankungen |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
JP2007532662A (ja) * | 2004-04-13 | 2007-11-15 | (オーエスアイ)アイテツク・インコーポレーテツド | 高分子量の立体的な基へ抱合された核酸アプタマー |
US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
EP3034089A1 (de) | 2004-11-02 | 2016-06-22 | Archemix LLC | Stabilisierte aptamere für einen aus plättchen gewonnenen wachstumsfaktor und deren verwendung als onkologietherapeutika |
WO2007005645A2 (en) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
JP2009510182A (ja) * | 2005-07-28 | 2009-03-12 | (オーエスアイ)アイテツク・インコーポレーテツド | シクリトールリンカーポリマー抱合体 |
US20090324551A1 (en) | 2005-08-22 | 2009-12-31 | The Regents Of The University Of California Office Of Technology Transfer | Tlr agonists |
KR100877824B1 (ko) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2epf ucp-vhl 상호작용 및 그 용도 |
TW200804425A (en) * | 2005-12-06 | 2008-01-16 | Domantis Ltd | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
WO2007069068A2 (en) * | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
JPWO2007080902A1 (ja) * | 2006-01-11 | 2009-06-11 | 協和発酵キリン株式会社 | 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤 |
EP1991275B1 (de) | 2006-03-08 | 2014-11-05 | Archemix LLC | Komplementbindende aptamere und anti-c5-wirkstoffe zur behandlung von augenleiden |
PL2125007T3 (pl) | 2007-02-07 | 2014-07-31 | Univ California | Koniugaty syntetycznych agonistów TLR i ich zastosowania |
US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
JP5971948B2 (ja) * | 2008-12-04 | 2016-08-17 | クルナ・インコーポレーテッド | Vegfに対する天然アンチセンス転写物の抑制による血管内皮増殖因子(vegf)関連疾患の治療 |
KR101800833B1 (ko) | 2009-03-20 | 2017-11-23 | 씨엘에스엔 래버러토리스, 인코퍼레이티드 | 폴리아민 유도체 |
EP2504436A1 (de) | 2009-11-23 | 2012-10-03 | INSERM - Institut National de la Santé et de la Recherche Médicale | Gegen matrixprotein-1 von typ-a-influenzaviren gerichtete aptamere und ihre verwendungen |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
CA2811601A1 (en) * | 2010-09-24 | 2012-03-29 | Mallinckrodt Llc | Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers |
US20150337308A1 (en) | 2012-04-11 | 2015-11-26 | Chu De Bordeaux | Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
EP2912182B1 (de) | 2012-10-23 | 2021-12-08 | Caris Science, Inc. | Aptamere und verwendungen davon |
AU2013361323B2 (en) | 2012-12-19 | 2018-09-06 | Caris Science, Inc. | Compositions and methods for aptamer screening |
WO2014148638A1 (ja) | 2013-03-22 | 2014-09-25 | 国立大学法人東京大学 | Il-17に対するアプタマー及びその使用 |
KR20220061248A (ko) | 2013-07-12 | 2022-05-12 | 이베릭 바이오, 인크. | 안과적 질환을 치료하거나 예방하기 위한 방법 |
JP2016533752A (ja) | 2013-08-28 | 2016-11-04 | カリス ライフ サイエンシズ スウィッツァーランド ホー | オリゴヌクレオチドプローブおよびその使用 |
PL3230316T3 (pl) | 2014-12-11 | 2022-05-02 | Bayer Healthcare Llc | Leczenie zwyrodnienia plamki żółtej związanego z wiekiem z małą aktywną zmianą neowaskularyzacji naczyniówki |
RU2723032C2 (ru) | 2014-12-29 | 2020-06-08 | Бонак Корпорейшн | Композиция, стабильно содержащая молекулу нуклеиновой кислоты |
AU2016229076B2 (en) | 2015-03-09 | 2022-01-20 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
US10590425B2 (en) | 2015-06-29 | 2020-03-17 | Caris Science, Inc. | Therapeutic oligonucleotides |
AU2016298317B2 (en) | 2015-07-28 | 2021-02-18 | Caris Science, Inc. | Targeted oligonucleotides |
WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
JP2019516393A (ja) | 2016-03-18 | 2019-06-20 | カリス サイエンス インコーポレイテッド | オリゴヌクレオチドプローブおよびその使用 |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
AU2017271579B2 (en) | 2016-05-25 | 2023-10-19 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
EP3332812A1 (de) | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nukleinsäurebasierte anordnung und verwendung der anordnung in der krebstherapie |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
JP7163288B2 (ja) | 2017-07-04 | 2022-10-31 | 第一三共株式会社 | 視細胞変性を伴う網膜変性疾患用薬 |
WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0462145B1 (de) * | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Kovalente konjugate von lipiden und oligonukleotiden |
US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US5849479A (en) * | 1990-06-11 | 1998-12-15 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
-
1997
- 1997-10-17 RU RU99110377/04A patent/RU2177950C2/ru active
- 1997-10-17 WO PCT/US1997/018944 patent/WO1998018480A1/en active IP Right Grant
- 1997-10-17 DE DE69735292T patent/DE69735292T2/de not_active Expired - Lifetime
- 1997-10-17 CA CA002269072A patent/CA2269072C/en not_active Expired - Lifetime
- 1997-10-17 DE DE200612000029 patent/DE122006000029I2/de active Active
- 1997-10-17 PT PT97912811T patent/PT957929E/pt unknown
- 1997-10-17 IL IL12949797A patent/IL129497A0/xx unknown
- 1997-10-17 NZ NZ334859A patent/NZ334859A/xx not_active IP Right Cessation
- 1997-10-17 KR KR10-1999-7003488A patent/KR100514929B1/ko not_active IP Right Cessation
- 1997-10-17 AU AU49904/97A patent/AU733674B2/en not_active Expired
- 1997-10-17 ES ES97912811T patent/ES2259188T3/es not_active Expired - Lifetime
- 1997-10-17 EP EP06003279A patent/EP1685842A3/de not_active Withdrawn
- 1997-10-17 GE GEAP199711120A patent/GEP20094799B/en unknown
- 1997-10-17 DK DK97912811T patent/DK0957929T3/da active
- 1997-10-17 EP EP97912811A patent/EP0957929B1/de not_active Expired - Lifetime
- 1997-10-17 JP JP52055398A patent/JP3626503B2/ja not_active Expired - Lifetime
- 1997-10-17 DE DE1997635292 patent/DE122006000029I1/de active Pending
- 1997-10-17 AT AT97912811T patent/ATE318143T1/de active
-
1999
- 1999-04-19 IL IL129497A patent/IL129497A/en not_active IP Right Cessation
-
2004
- 2004-10-15 JP JP2004301813A patent/JP4160038B2/ja not_active Expired - Lifetime
-
2006
- 2006-06-14 LU LU91252C patent/LU91252I2/fr unknown
- 2006-07-03 FR FR06C0021C patent/FR06C0021I2/fr active Active
- 2006-07-20 NL NL300234C patent/NL300234I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
DK0957929T3 (da) | 2006-07-03 |
PT957929E (pt) | 2006-06-30 |
JP3626503B2 (ja) | 2005-03-09 |
CA2269072C (en) | 2006-02-14 |
KR100514929B1 (ko) | 2005-09-15 |
KR20000052697A (ko) | 2000-08-25 |
IL129497A (en) | 2009-06-15 |
FR06C0021I1 (de) | 2006-10-13 |
AU733674B2 (en) | 2001-05-24 |
JP4160038B2 (ja) | 2008-10-01 |
JP2005046160A (ja) | 2005-02-24 |
AU4990497A (en) | 1998-05-22 |
DE69735292D1 (de) | 2006-04-27 |
EP1685842A2 (de) | 2006-08-02 |
LU91252I2 (fr) | 2006-08-14 |
EP0957929A1 (de) | 1999-11-24 |
DE122006000029I1 (de) | 2006-10-19 |
EP1685842A3 (de) | 2006-11-29 |
CA2269072A1 (en) | 1998-05-07 |
DE69735292T2 (de) | 2006-10-19 |
RU2177950C2 (ru) | 2002-01-10 |
IL129497A0 (en) | 2000-02-29 |
NZ334859A (en) | 2001-02-23 |
NL300234I1 (nl) | 2006-09-01 |
ES2259188T3 (es) | 2006-09-16 |
EP0957929A4 (de) | 2003-06-25 |
EP0957929B1 (de) | 2006-02-22 |
DE122006000029I2 (de) | 2007-11-08 |
GEP20094799B (en) | 2009-10-26 |
NL300234I2 (nl) | 2006-10-02 |
FR06C0021I2 (fr) | 2007-08-03 |
JP2001505191A (ja) | 2001-04-17 |
WO1998018480A1 (en) | 1998-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE318143T1 (de) | Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe | |
DE69638099D1 (de) | Nukleinsäureligand-komplexe | |
CY1114352T1 (el) | Συμπλοκα συνδετηρων νουκλεϊνικου οξεος παραγοντα αναπτυξης που λαμβανεται απο αιμοπεταλιο (pdgf) | |
DE69730820D1 (de) | Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel | |
DE3575208D1 (de) | Optischer, integrierter hybridschaltkreis und verfahren zu seiner herstellung. | |
DE69109131T2 (de) | Verfahren zur herstellung von molekularsieben, einschliesslich zeolithen, mit metallchelat-komplexen. | |
DE58903401D1 (de) | Cyclohexenonoximether, verfahren zu ihrer herstellung und ihre verwendung als herbizid. | |
NO885836D0 (no) | Kvantitativ metode for bestemmelse av 1,4-dihydronikotinamid-adenin-dinukleotid i opploesning. | |
DE3670858D1 (de) | Wasserloesliche triphendioxazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
DE69005903D1 (de) | Verstärkungsgerät mit Differenzverstärkerstufe. | |
DE3768452D1 (de) | Wasserloesliche farbige verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
ATE428500T1 (de) | Kunststoff-geträgerte phosphorliganden verwendbar in der katalyse | |
DE3582702D1 (de) | Neue metallkomplexe, verfahren zu ihrer herstellung ihre verwendung zum faerben von hochmolekularem organischem material. | |
DE3875512D1 (de) | Dufterzeugnis mit gesteuerter abgabe und verfahren zu seiner herstellung. | |
DE3880991T2 (de) | Aminoanthracendion-bis-platinkomplexe, nützlich als Antitumor-Agenzien. | |
DE3862331D1 (de) | Wasserloesliche azoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
DeTreville | SENATUS ET RELIGIO: ASPECTS OF THE ROMAN SENATE'S ROLE IN THE STATE RELIGION DURING THE REPUBLIC. | |
DE69003107T2 (de) | Mit bor komplexierte organische phosphor-verbindungen. | |
DE58904373D1 (de) | Wasserloesliche 2-naphthol-azoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
DE3765050D1 (de) | Wasserloesliche triphendioxazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
DE58903335D1 (de) | Neue aromatische polyethersulfone, verfahren zu ihrer herstellung und ihre verwendung. | |
ATE89284T1 (de) | Aminoanthracendion-bis-platinkomplexe, nuetzlich als antitumor-agenzien. | |
DE3882416T2 (de) | Aus zwei Teilen vormontierter Haken für Warenauslage, sowie Verfahren und Vorrichtung zu dessen Herstellung. | |
DE59102844D1 (de) | Wasserlösliche faserreaktive farbstoffe, verfahren zu ihrer herstellung und ihre verwendung. | |
SI0957929T1 (sl) | Kompleksi liganda nukleinske kisline vaskularnegaendotelijskega rastnega faktorja (VEGF) |